'Don't break what's working,' FDA's Woodcock urges Congress
This article was originally published in Scrip
Executive Summary
As Congress considers actions to better enable the progress of US biomedical innovation, Dr Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research (CDER), pleaded "don't break what is working," but instead, "improve on the current system."